These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 31852909)

  • 1. Focused ultrasound enhanced intranasal delivery of brain derived neurotrophic factor produces neurorestorative effects in a Parkinson's disease mouse model.
    Ji R; Smith M; Niimi Y; Karakatsani ME; Murillo MF; Jackson-Lewis V; Przedborski S; Konofagou EE
    Sci Rep; 2019 Dec; 9(1):19402. PubMed ID: 31852909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-invasive, neuron-specific gene therapy by focused ultrasound-induced blood-brain barrier opening in Parkinson's disease mouse model.
    Lin CY; Hsieh HY; Chen CM; Wu SR; Tsai CH; Huang CY; Hua MY; Wei KC; Yeh CK; Liu HL
    J Control Release; 2016 Aug; 235():72-81. PubMed ID: 27235980
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Social enrichment attenuates nigrostriatal lesioning and reverses motor impairment in a progressive 1-methyl-2-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease.
    Goldberg NR; Fields V; Pflibsen L; Salvatore MF; Meshul CK
    Neurobiol Dis; 2012 Mar; 45(3):1051-67. PubMed ID: 22198503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MPTP-induced dopaminergic neurotoxicity in mouse brain is attenuated after subsequent intranasal administration of (R)-ketamine: a role of TrkB signaling.
    Fujita A; Fujita Y; Pu Y; Chang L; Hashimoto K
    Psychopharmacology (Berl); 2020 Jan; 237(1):83-92. PubMed ID: 31418048
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulatable Lentiviral Hematopoietic Stem Cell Gene Therapy in a Mouse Model of Parkinson's Disease.
    Ge G; Chen C; Guderyon MJ; Liu J; He Z; Yu Y; Clark RA; Li S
    Stem Cells Dev; 2018 Jul; 27(14):995-1005. PubMed ID: 29562865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Telmisartan attenuates MPTP induced dopaminergic degeneration and motor dysfunction through regulation of α-synuclein and neurotrophic factors (BDNF and GDNF) expression in C57BL/6J mice.
    Sathiya S; Ranju V; Kalaivani P; Priya RJ; Sumathy H; Sunil AG; Babu CS
    Neuropharmacology; 2013 Oct; 73():98-110. PubMed ID: 23747572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes of tyrosine hydroxylase in parkinsonian brains and in the brains of MPTP-treated mice.
    Nagatsu T
    Adv Neurol; 1990; 53():207-14. PubMed ID: 1978515
    [No Abstract]   [Full Text] [Related]  

  • 8. Neuroprotection in Parkinson models varies with toxin administration protocol.
    Anderson DW; Bradbury KA; Schneider JS
    Eur J Neurosci; 2006 Dec; 24(11):3174-82. PubMed ID: 17156378
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The mesolimbic dopaminergic pathway is more resistant than the nigrostriatal dopaminergic pathway to MPTP and MPP+ toxicity: role of BDNF gene expression.
    Hung HC; Lee EH
    Brain Res Mol Brain Res; 1996 Sep; 41(1-2):14-26. PubMed ID: 8883930
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fingolimod (FTY720) is not protective in the subacute MPTP mouse model of Parkinson's disease and does not lead to a sustainable increase of brain-derived neurotrophic factor.
    Komnig D; Dagli TC; Habib P; Zeyen T; Schulz JB; Falkenburger BH
    J Neurochem; 2018 Dec; 147(5):678-691. PubMed ID: 30152864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene dysregulation is restored in the Parkinson's disease MPTP neurotoxic mice model upon treatment of the therapeutic drug Cu(II)(atsm).
    Cheng L; Quek CY; Hung LW; Sharples RA; Sherratt NA; Barnham KJ; Hill AF
    Sci Rep; 2016 Mar; 6():22398. PubMed ID: 26928495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of nigrostriatal neurodegeneration and neuroinflammation following repeated intranasal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration in mice, an experimental model of Parkinson's disease.
    Tristão FS; Amar M; Latrous I; Del-Bel EA; Prediger RD; Raisman-Vozari R
    Neurotox Res; 2014 Jan; 25(1):24-32. PubMed ID: 23690159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic effects of paeonol on methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid-induced Parkinson's disease in mice.
    Shi X; Chen YH; Liu H; Qu HD
    Mol Med Rep; 2016 Sep; 14(3):2397-404. PubMed ID: 27484986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Electroacupuncture Therapy Ameliorates Motor Dysfunction via Brain-Derived Neurotrophic Factor and Glial Cell Line-Derived Neurotrophic Factor in a Mouse Model of Parkinson's Disease.
    Pak ME; Ahn SM; Jung DH; Lee HJ; Ha KT; Shin HK; Choi BT
    J Gerontol A Biol Sci Med Sci; 2020 Mar; 75(4):712-721. PubMed ID: 31644786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a new rodent model to test palliative and neuroprotective agents for Parkinson's disease.
    Prediger RD; Aguiar AS; Moreira EL; Matheus FC; Castro AA; Walz R; De Bem AF; Latini A; Tasca CI; Farina M; Raisman-Vozari R
    Curr Pharm Des; 2011; 17(5):489-507. PubMed ID: 21375482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overlesioned hemiparkinsonian non human primate model: correlation between clinical, neurochemical and histochemical changes.
    Oiwa Y; Eberling JL; Nagy D; Pivirotto P; Emborg ME; Bankiewicz KS
    Front Biosci; 2003 Sep; 8():a155-66. PubMed ID: 12957824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
    Novikova L; Garris BL; Garris DR; Lau YS
    Neuroscience; 2006 Jun; 140(1):67-76. PubMed ID: 16533572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estrogen reduces BDNF level, but maintains dopaminergic cell density in the striatum of MPTP mouse model.
    Tripanichkul W; Gerdprasert O; Jaroensuppaperch EO
    Int J Neurosci; 2010 Jul; 120(7):489-95. PubMed ID: 20583901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuroprotective effect of silymarin in a MPTP mouse model of Parkinson's disease.
    Pérez-H J; Carrillo-S C; García E; Ruiz-Mar G; Pérez-Tamayo R; Chavarría A
    Toxicology; 2014 May; 319():38-43. PubMed ID: 24607817
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Focused Ultrasound Promotes the Delivery of Gastrodin and Enhances the Protective Effect on Dopaminergic Neurons in a Mouse Model of Parkinson's Disease.
    Wang Y; Luo K; Li J; Liao Y; Liao C; Chen WS; Chen M; Ao L
    Front Cell Neurosci; 2022; 16():884788. PubMed ID: 35656407
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.